BPIQ Blog

Aug 7, 20231 min read

SYFOVRE (APLS) vs. IZERVAY (Astellas)

Tough month for APLS • 1st: safety issue surfaces for SYFOVRE ⇨ Retinal Vasculitis • Now: IZERVAY approved early ⇨ Good for AMD patients...

Jump start your biotech due diligence

Our platform helps you uncover your next biotech investment opportunity

bottom of page